BARCELONA, Spain — Annual dosing of rituximab for relapsing-remitting multiple sclerosis (RRMS) was noninferior to the typical dosing schedule of once every 6 months, which could offer a more ...
A trial evaluated whether rituximab can attain remission in adults with frequently relapsing nephrotic syndrome (FRNS) or steroid dependent nephrotic syndrome (SDNS).
One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic ...
The US Food and Drug Administration today announced it has approved Danish biotech firm Genmab’s Epkinly (epcoritamab-bysp) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback